Journals / Retina-Vitreus / 2014 / Cilt: 22 - Sayı: 2

Endogenous Candida Endophthalmitis: Treatment options

Endojen Kandida Endoftalmisi: Tedavi seçenekleri

Pages
159–167
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this report, we aim to present diagnosis and treatment management of a patient who carries many risk factors for the development of invasive candida infection and eventually developed candida endophthalmitis, and also treatment options for ECE cases in the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Endogenous fungal endophthalmitis(EFE) is a rare infection, but it maintains its importance in ophthalmology because of high potential to cause severe visual loss and also due to the limited treatment options.Candida albicans is the most common cause of EFE.
📊
Key Findings & Data:There is an increase in the incidence of EFE by the increase of intravenous drug abuse, indwelling venous access devices, long-term antibiotic, corticosteroid or immunosuppressive drug use.For the management of treatment in ECE, we should consider that ECE develops after the candidemia due to invasive infection, and also delayed diagnosis and treatment may lead to vision loss.
💡
Conclusion & Impact:In this report, we aim to present diagnosis and treatment management of a patient who carries many risk factors for the development of invasive candida infection and eventually developed candida endophthalmitis, and also treatment options for ECE cases in the literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Endogenous fungal endophthalmitis(EFE) is a rare infection, but it maintains its importance in ophthalmology because of high potential to cause severe visual loss and also due to the limited treatment options.Candida albicans is the most common cause of EFE. Endogenous candida endophthalmitis (ECE) generally occur in patients with risk factors although we can’t prove the presence of candidemia. There is an increase in the incidence of EFE by the increase of intravenous drug abuse, indwelling venous access devices, long-term antibiotic, corticosteroid or immunosuppressive drug use.For the management of treatment in ECE, we should consider that ECE develops after the candidemia due to invasive infection, and also delayed diagnosis and treatment may lead to vision loss. More importantly, we should consider that patients have a life-threatening infection. Because ECE patients have systemic medical illnesses, we should not forgotten they need a multidisciplinary management.In the presence of a simple choroiditis or mild vitritis systemic antifungal agents can be effective alone.However, in the presence of moderate-to-severe vitritis or macular involvement associated with severe vi- sion loss, pars plana vitrectomy and/or intravitreal injection of amphotericin B has been generally preferred in addition to systemic treatment. In this report, we aim to present diagnosis and treatment management of a patient who carries many risk factors for the development of invasive candida infection and eventually developed candida endophthalmitis, and also treatment options for ECE cases in the literature.

Özet

Endojen fungal endoftalmi (EFE) nadir görülen bir enfeksiyon olmasına rağmen ağır görme kaybına yol açma potansiyeli- nin yüksek olması ayrıca tedavi seçeneklerinin limitli olması nedeniyle oftalmolojide önemini korumaktadır. Endojen endof- talmilerin en sık nedeni olan fungal ajanların başında kandida albikans gelmektedir. Birçok endojen kandida endoftalmisi (EKE), kandidemi varlığı ortaya konamasa da risk faktörü olan hastalarda ortaya çıkmaktadır. İntravenöz madde kötüye kullanımının, uzun süreli kalıcı katater girişimlerinin, uzun süreli antibiyotik, kortikosteroid veya immunsupresif ilaç kullanımının artmasıyla EFE insidansında artış görülmektedir. Erken tanı ve tedavi görsel prognoz açısından büyük önem taşımaktadır. Tedavi yaklaşımında; endojen endoftalmi tablosunun invaziv kandida enfeksiyonuna bağlı kandidemi sonra- sında geliştiğini, geç tanı ve tedavinin görme kaybına neden olabileceği gibi daha da önemlisi hastaların hayati risklerinin olduğunu göz önünde bulundurmak gerekir. Genelikle sistemik medikal rahatsızlığı olan hastalar olmaları sebebiyle EKE hastalarının tedavi ve takibinde multidisipliner bir yaklaşım gerektiğini unutmamak gerekir. Endojen endoftalmi, koryo- retinit olarak başlayıp vitrite doğru ilerlediği için basit koroidit veya hafif şiddetli vitrit varlığında sistemik antifungaller tek başına etkili olabilmektedir. Ciddi görme kaybının eşlik ettiği makuler tutulum veya orta-ağır şiddetli vitrit varlığında, sistemik antifungal tedavisine ek olarak pars plana vitrektomi ve/veya intravitreal amfoterisin B enjeksiyonu genellikle kabul gören tedavi şekli olmuştur. Bu makalede, invaziv kandida enfeksiyonu gelişimi için çok sayıda risk faktörü taşıyan ve neticede kandida endoftalmisi gelişen bir olgunun tanı ve tedavi süreci ile beraber literatürdeki EKE vakalarına yönelik tedavi yaklaşımlarını sunmayı amaçladık.

🔖

Cite This Article

DÜZGÜN, E., ÇAKIR, A., ÜNAL, M. H., SÖNMEZ, M., AYATA, A., YILDIRIM, Y., KARAGÖZ, E. (2014). Endogenous Candida Endophthalmitis: Treatment options. Retina-Vitreus, Cilt: 22 - Sayı: 2, 159–167. https://ajindex.com/articles/308050

References (14)

  1. Schiedler V, Scott IU, Flynn Jr HW, et al. Culture-proven en- dogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol 2004;137:725-31
  2. Chang T.S, Chen w.C, Chen H.S, et al. Endogenous candida endophthalmitis after two consecutive procedures of suc- tion dilatation and curettage, Chang Gung Medical Journal 2002;25:778-82. 3. Šikiæ J, Vukojeviæ N, Katušiæ D, et al., Bilateral Endogenous Candida Endophthalmitis after Induced Abortion,Croatia Croat Medical Journal 2001;42:676-8
  3. Samiy N, D’Amico DJ. Endogenous fungal endophthalmitis. Int Ophthalmol Clin 1996;36:147-62
  4. Essman TF, Flynn HW Jr, Smiddy WE, et al. Treatment out- comes in a 10-year study of endogenous fungal endophthalmi- tis. Ophthalmic Surg Lasers 1997;28:185-94. 6.Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: fo- cus on current and future antifungal treatment options. Phar- macotherapy 2007;27:1711-21
  5. Holland G. Endogenous fungal infection of the retina and choroid. In:Ryan SJ, ed. Retina, 4th ed. St. Louis: Mosby 2005:1683-98
  6. Scherer WJ, Lee K, Implications of early systemic therapy on the incidence of endogenous fungal endophthalmitis. Oph- thalmology 1997;104:1593
  7. Najmi NG, Song HF, Ober RR., Presumed Candida endog- enous fungal endophthalmitis:A case report and literature review, Optometry 2007;78:454-9
  8. Smiddy WE, Treatment outcomes of endogenous fungal end- oftalmitis, Current Opinion in Ophthalmology 1998;9:66-70
  9. Binder MI, Chua J, Kaiser PK,et al. Endogenous endophthal- mitis. An 18-year review of culture-positive cases at a tertiary center. Medicine 2003;82:97-105
  10. Ness T., Pelz K., Hansen LL. Endogenous endophthalmitis: microorganisms, disposition and prognosis. Acta Ophthalmo- logica Scandinavica 2007;85:852-6
  11. Hidalgo JA., Alangaden GJ., Eliott D. et al. Fungal endophthal- mitis diagnosis by detection of candida albicans dna in ıntraocular fluid by use of a species-specific polymerase chain reaction assay, The Journal of Infectious Diseases 2000;181:1198-201
  12. Ogawa M, Sugita S, Watanabe K, et al., Novel diagnosis of fungal endophthalmitis by broad-range real-time PCR detec- tion of fungal 28S ribosomal DNA. Graefes Arch Clin Exp Ophthalmol 2012;250:1877-83
  13. Anand A, Madhavan H, Neelam V, et al. Use of polymerase chain reaction in the diagnosis of fungal endophthalmitis. Ophthalmology 2001;108:326-30
  14. Riddell J, Comer GM, Kauffman CA. Treatment of endoge- nous fungal endophthalmitis: focus on